Novavax (NVAX) Reports Q2, Issues Operational Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Wall St futures rise as Treasury yields cool, oil slips
- Oil slips as Mideast exports, G7 stockpile ease supply concerns
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Citi cuts investment banking analyst program to two years - Bloomberg
- Paramount Skydance to close WBD deal, change ticker to SKYD
- HubSpot to cut 7% of workforce in restructuring plan
- Nasdaq notches record high close as investors focus on earnings
- Francis Halzen wins Nobel Physics Prize for Antarctic 'ghost particle' hunt
Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
August 8, 2024 8:02 AM EDTAchieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in CashFiled with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccineReceived $570 million in upfront payment and equity investment from Sanofi; progressed operationalization of Sanofi partnershipPhase 3 trial initiation for COVID-19-Influenza Combination and stand-alone influenza vaccines planned for Q4 2024; data expected by mid-2025Company to host conference call today at 8:30 a.m.... More



